Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTA3263 in advanced solid tumors with KRAS mutations
NCT06835569Phase 1Recruiting
- Sponsor
- Alterome Therapeutics
- Start
- Mar 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALTA3263 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (10 arms), sponsored by Alterome Therapeutics. Primary endpoints: Adverse Events up to 39 months and Dose Limiting Toxicities at 21 days. Started Mar 2025; status: recruiting.
02
Drugs
ALTA3263
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06835569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835569.